Eli Lilly: Taltz meets goal in late-stage trial

(CercleFinance.com) - Eli Lilly said on Tuesday that its monoclonal antibody Taltz, which blocks inflammatory and immune responses, has met its primary and key secondary endpoints in a late-stage study involving ankylosing spondylitis patients.


The Phase III results showed that the drug demonstrated a statistically significant improvement in the signs and symptoms of the disease, the US drugmaker said.

A chronic, debilitating disease, ankylosing spondylitis affects the joints and spine and is characterized by chronic inflammatory back pain, stiffness and impaired mobility.

The NYSE-listed shares were almost unchanged after the news, down 0.2% at 76.1 dollars.

Copyright (c) 2018 CercleFinance.com. All rights reserved.